Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Nutraceutical

PUBLISHER: 360iResearch | PRODUCT CODE: 1923794

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1923794

Bifidobacterium Longum Subsp. Infantis M-63 Market by Application, Form, End User, Distribution Channel - Global Forecast 2026-2032

PUBLISHED:
PAGES: 184 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (2-5 User License)
USD 4249
PDF, Excel & 1 Year Online Access (Site License)
USD 5759
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

Description

Table of Contents

List of Tables

The Bifidobacterium Longum Subsp. Infantis M-63 Market was valued at USD 540.19 million in 2025 and is projected to grow to USD 585.64 million in 2026, with a CAGR of 9.25%, reaching USD 1,003.50 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 540.19 million
Estimated Year [2026] USD 585.64 million
Forecast Year [2032] USD 1,003.50 million
CAGR (%) 9.25%

Comprehensive introduction to the biological properties, clinical relevance, and commercial potential of a specialized infant-derived probiotic strain

Bifidobacterium longum subsp. infantis M-63 occupies a distinct position at the intersection of infant microbiome science and applied probiotic development. This organism has attracted attention for its specialized carbohydrate metabolism and its capacity to colonize the neonatal gut ecosystem during a critical window of immunological and metabolic programming. Beyond neonatal applications, the strain's functional attributes have prompted exploration across dietary supplements, functional foods, and adjunctive therapeutic contexts where targeted modulation of the gut microbiota can influence host physiology.

The maturation of analytical platforms and a surge in mechanistic studies have deepened understanding of strain-specific activity, safety profiles, and synergistic potentials with prebiotics and bioactive matrices. Consequently, manufacturers, clinicians, and regulatory stakeholders increasingly value evidence that connects in vitro activity and preclinical signals to clinically meaningful outcomes. As stakeholders navigate complex pathways from R&D to commercial deployment, they must balance rigorous clinical substantiation with scalable manufacturing, stability in diverse product formats, and compliance across multiple regulatory frameworks.

Given these dynamics, strategic planning around formulation, route-to-market, and cross-functional collaboration becomes essential. Firms that integrate clinical research with product design and supply chain resilience will be better positioned to translate the biological promise of the strain into differentiated products that meet both caregiver expectations and regulatory scrutiny.

Evolving scientific, regulatory, and commercial dynamics reshaping probiotic development, delivery, and supply chain resilience across infant and clinical markets

Recent years have brought transformative shifts that affect how stakeholders conceive, develop, and commercialize probiotic strains intended for neonatal and broader human health applications. Advances in next-generation sequencing and metabolomics now enable high-resolution characterization of microbial-host interactions, revealing strain-level mechanisms that inform targeted therapeutic hypotheses. At the same time, product innovation has moved beyond single-format offerings to multi-modal delivery strategies that prioritize stability, targeted release, and consumer convenience.

Regulatory pathways have evolved in parallel, with a stronger emphasis on clinically relevant endpoints, quality-by-design manufacturing, and demonstrable safety in vulnerable populations. These changes have pushed developers to integrate clinical validation earlier in the product lifecycle, and to adopt robust quality assurance systems that support international dossiers. Meanwhile, commercial dynamics reflect a growing convergence between infant nutrition, clinical probiotic therapeutics, and lifestyle supplements, creating cross-sector partnerships between nutraceutical companies, infant-formula manufacturers, and clinical research organizations.

Furthermore, supply chain resilience and ingredient traceability have gained prominence as procurement teams face unpredictable raw material flows and rising expectations for transparency. Taken together, these shifts require a multidisciplinary approach to strategy that aligns scientific rigor with pragmatic considerations for scale, differentiation, and patient safety.

Assessment of how recent tariff adjustments have altered supply chain economics, manufacturing decisions, and procurement strategies for specialized probiotic products

The policy landscape in 2025 introduced tariff adjustments that exert material influence on cross-border trade flows for specialty biological ingredients and finished probiotic products. Tariff changes have amplified cost pressures at multiple nodes in the value chain, from raw ingredient sourcing through to finished-product distribution. As a result, procurement teams have intensified supplier diversification and nearshoring evaluations to mitigate exposure to sudden tariff-driven cost variability.

Manufacturers reliant on international supply of carrier materials, excipients, or contract-manufactured dosage forms now face higher landed costs that can compress margins unless offset by efficiency gains or price adjustments. In response, companies have prioritized process optimization and negotiated longer-term supplier agreements to stabilize input costs. Concurrently, some firms have accelerated investments in domestic production capabilities and technology transfer to reduce reliance on tariff-sensitive import corridors.

Regulatory compliance and documentation requirements interact with tariff impacts, since re-routing supply chains or shifting manufacturing footprints often triggers additional registration or quality audits in new jurisdictions. For product developers, the combined effect of tariffs and regulatory friction has heightened the importance of scenario planning, tax-efficient logistics, and adaptive pricing strategies. In the near term, market participants that proactively align procurement, legal, and commercial teams will manage tariff-driven disruptions more effectively and preserve strategic flexibility for future growth.

In-depth segmentation framework revealing application, form, end-user, and channel distinctions to guide product development and go-to-market strategies

A nuanced segmentation framework clarifies the diverse end-use contexts for the strain and indicates where strategic focus can generate disproportionate value. Based on application, stakeholders should evaluate opportunities across animal feed, dietary supplements, functional foods, infant formula, and pharmaceuticals. Within animal feed, opportunities diverge across aquaculture feed, livestock feed, and pet food, each with distinct regulatory expectations and formulation constraints. The dietary supplements arena differentiates adult supplements, elderly supplements, and infant supplements, reflecting varied dosing, labeling, and safety considerations. Functional foods present pathways through beverages, dairy products, and snack bars, which demand tailored stability and sensory strategies. Infant formula applications span cow milk-based, hypoallergenic, and soy-based platforms, each requiring careful compatibility and clinical substantiation. Pharmaceutical applications separate into adjunctive therapies and probiotic therapeutics, where clinical endpoints and manufacturing standards escalate in rigor.

When considering form, product teams must address capsule, liquid, powder, and tablet presentations, with capsule design further distinguishing enteric-coated and non-enteric variants for targeted release profiles. Form-driven choices influence shelf-life, cold-chain needs, and consumer convenience, so cross-functional coordination between formulation scientists and commercial strategists is essential. End user segmentation calls for differentiated messaging and safety evidence tailored to adults, children, elderly, and infants, with infant-focused claims demanding the most stringent clinical and regulatory support.

Distribution channel analysis highlights direct sales, e-commerce, hospitals, and retail pharmacies as principal pathways. Direct sales split into direct marketing and healthcare practitioner channels, each requiring distinct sales enablement and compliance approaches. E-commerce divides into direct-to-consumer and third-party platforms, influencing packaging, logistics, and digital marketing tactics. Hospitals are segmented into private and public institutions and often necessitate tendering and bulk supply arrangements. Retail pharmacies separate into chain and independent outlets, which differ in category management and promotional levers. Together, this layered segmentation informs product design, clinical strategy, and go-to-market execution for organizations pursuing differentiated positioning in competitive probiotic markets.

Comparative regional analysis outlining regulatory complexities, channel dynamics, and consumer drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics influence regulatory thresholds, caregiver preferences, and commercialization pathways, making geography a determinant of strategic priorities. In the Americas, established infant-nutrition markets emphasize regulatory compliance and clinical substantiation, while commercial channels balance traditional retail pharmacies with a rapidly growing direct-to-consumer e-commerce presence. Manufacturers in this region often leverage robust clinical trial networks and sophisticated lab infrastructure to generate evidence that supports premium positioning.

Across Europe, Middle East & Africa, regulatory harmonization efforts and varied national frameworks create a complex mosaic for market entry. Stakeholders must navigate divergent labeling rules, clinical evidence expectations, and import requirements, and they frequently adopt modular regulatory strategies that prioritize lead markets for initial launches. In parts of the region, demand is rising for clean-label, traceable ingredients, and healthcare systems increasingly evaluate probiotic interventions through the lens of cost-effectiveness and clinical outcome data.

Asia-Pacific presents high-growth aspirations driven by demographic trends, rising disposable incomes, and strong interest in infant nutrition and preventive health. Local manufacturing capacity is expanding, and market participants often tailor formulations and communication strategies to culturally specific feeding practices and regulatory regimes. Across all regions, firms that reconcile global standards with local adaptation-aligning clinical evidence, manufacturing quality, and distribution models-will capture opportunities while managing compliance complexity and consumer trust concerns.

Competitive landscape and corporate strategies emphasizing clinical validation, manufacturing scale-up, and partnership-driven acceleration for market advantage

Competitive positioning in this space revolves around scientific differentiation, manufacturing capability, and evidence generation. Leading organizations are investing in controlled clinical studies that demonstrate strain-specific benefits and safety in target populations, thereby enabling premium claims and stronger uptake among healthcare professionals. Intellectual property strategies frequently combine strain deposits, process patents, and proprietary formulations to create defensible commercial moats.

Strategic partnerships between ingredient suppliers, contract manufacturers, infant-formula producers, and clinical research organizations accelerate time-to-market and broaden technical capabilities. Contract development and manufacturing organizations that offer integrated sterile handling, lyophilization, and encapsulation services play a pivotal role in scaling production while maintaining viability and potency. In parallel, investment in quality management systems and global regulatory expertise enhances the ability of companies to support multi-jurisdictional registrations.

Mergers, acquisitions, and licensing deals continue to shape the competitive landscape, with larger firms acquiring specialized strains or capabilities to supplement their existing portfolios. Smaller innovators differentiate through niche clinical programs or targeted distribution strategies. Across company types, those that align clinical evidence with scalable manufacturing and disciplined regulatory execution will achieve the most sustained advantage in the evolving probiotic marketplace.

Practical and prioritized strategic recommendations for aligning clinical programs, formulation development, procurement resilience, and commercialization to accelerate product success

Industry leaders must prioritize a coordinated approach that spans scientific validation, product design, and supply chain strategy to convert biological promise into reliable commercial outcomes. First, align clinical programs with intended product claims and end-user needs, ensuring study populations and endpoints reflect real-world usage and regulatory expectations. Where possible, integrate adaptive trial designs to accelerate learning and focus investment on the most promising clinical hypotheses.

Second, invest in formulation science to preserve viability across targeted delivery formats, selecting excipients, encapsulation technologies, and packaging systems that match distribution realities and consumer preferences. This approach reduces downstream stability risks and supports broader channel adoption. Third, fortify procurement by diversifying supplier bases, exploring nearshoring options, and negotiating performance-based supply agreements that incorporate quality metrics and contingencies.

Fourth, build cross-functional commercialization plans that synchronize regulatory submissions, manufacturing scale-up, and channel-specific launch tactics. Engage healthcare professionals early to create education pathways and evidence dissemination strategies that enhance clinical acceptance. Finally, adopt metrics-driven post-market surveillance and real-world evidence programs to continuously validate product performance, inform iterative improvements, and sustain trust among clinicians and caregivers.

Transparent explanation of a mixed-methods research approach combining expert interviews, literature synthesis, and scenario-based analysis to generate actionable insights

The underlying research approach combined structured primary engagement with domain experts and a comprehensive review of publicly available scientific and regulatory literature to ensure balanced, evidence-focused conclusions. Primary inputs included interviews with clinicians, formulation scientists, manufacturing specialists, procurement managers, and regulatory advisors who provided qualitative insight into clinical priorities, production constraints, and channel dynamics. These conversations informed hypothesis generation and helped prioritize topics for deeper technical review.

Secondary research encompassed peer-reviewed studies, regulatory guidance documents, and product specifications to triangulate mechanistic understanding and safety considerations. Data synthesis emphasized strain-specific findings and cross-validated manufacturing and stability reports to ensure practical relevance. Analytical methods included comparative scenario analysis to explore supply chain contingencies and sensitivity assessments to identify operational levers that mitigate policy or cost shocks.

Throughout the process, the research team applied quality checks including source triangulation, expert validation, and iterative drafting cycles with domain reviewers. This methodology ensured that insights reflect both the current scientific consensus and operational realities, providing actionable guidance without making quantitative market projections. The result is an evidence-grounded narrative that supports strategic decision-making across research, regulatory planning, and commercial execution.

Conclusive synthesis highlighting the necessity of integrated scientific validation, operational rigor, and region-sensitive commercialization for long-term product success

The synthesis of scientific, regulatory, and commercial perspectives underscores that translating the potential of highly specific probiotic strains into sustainable products requires integrated execution across multiple functions. Strain selection and clinical validation remain foundational, but they must be complemented by formulation strategies that ensure viability in intended formats and distribution environments. At the same time, supply chain and regulatory planning must be proactive, with contingency measures to manage tariff and trade uncertainties as well as jurisdictional registration requirements.

Successful market entrants will combine robust clinical evidence with manufacturing excellence and tailored go-to-market approaches that respect regional differences in regulation and consumer behavior. Partnerships and licensing arrangements can accelerate capability build-out, while adaptive pricing and procurement strategies can mitigate short-term cost pressures. Ultimately, organizations that marry scientific credibility with operational discipline and market sensitivity will create durable competitive advantage and deliver meaningful benefits to caregivers and patients.

As the field continues to evolve, ongoing investment in clinical studies, real-world evidence collection, and technology-driven manufacturing will determine which products achieve broad clinical acceptance and long-term commercial viability. Stakeholders that adopt a learning orientation and continuously align evidence generation with product development priorities will be best positioned to seize emerging opportunities.

Show more
Product Code: MRR-7A380DA7C2B9

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Application

  • 8.1. Animal Feed
    • 8.1.1. Aquaculture Feed
    • 8.1.2. Livestock Feed
    • 8.1.3. Pet Food
  • 8.2. Dietary Supplements
    • 8.2.1. Adult Supplements
    • 8.2.2. Elderly Supplements
    • 8.2.3. Infant Supplements
  • 8.3. Functional Foods
    • 8.3.1. Beverages
    • 8.3.2. Dairy Products
    • 8.3.3. Snack Bars
  • 8.4. Infant Formula
    • 8.4.1. Cow Milk-Based
    • 8.4.2. Hypoallergenic
    • 8.4.3. Soy-Based
  • 8.5. Pharmaceuticals
    • 8.5.1. Adjunctive Therapies
    • 8.5.2. Probiotic Therapeutics

9. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Form

  • 9.1. Capsule
    • 9.1.1. Enteric-Coated
    • 9.1.2. Non-Enteric
  • 9.2. Liquid
  • 9.3. Powder
  • 9.4. Tablet

10. Bifidobacterium Longum Subsp. Infantis M-63 Market, by End User

  • 10.1. Adults
  • 10.2. Children
  • 10.3. Elderly
  • 10.4. Infants

11. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bifidobacterium Longum Subsp. Infantis M-63 Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bifidobacterium Longum Subsp. Infantis M-63 Market

16. China Bifidobacterium Longum Subsp. Infantis M-63 Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. BioGaia AB
  • 17.6. Chr. Hansen A/S
  • 17.7. Danone S.A.
  • 17.8. DuPont de Nemours, Inc.
  • 17.9. Evolve Biosystems
  • 17.10. Fengchen Group Co., Ltd.
  • 17.11. Fido Pharma Pvt. Ltd.
  • 17.12. Kerry Group plc
  • 17.13. Lallemand Inc.
  • 17.14. Mead Johnson Nutrition
  • 17.15. Molkem
  • 17.16. Morinaga Milk Industry Co., Ltd.
  • 17.17. Nestle S.A.
  • 17.18. Probi AB
  • 17.19. Yakult Honsha Co., Ltd.
Show more
Product Code: MRR-7A380DA7C2B9

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY AQUACULTURE FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY AQUACULTURE FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY AQUACULTURE FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PET FOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PET FOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PET FOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADULT SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADULT SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADULT SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ELDERLY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ELDERLY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ELDERLY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY BEVERAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY BEVERAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY BEVERAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DAIRY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DAIRY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DAIRY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SNACK BARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SNACK BARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SNACK BARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COW MILK-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COW MILK-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COW MILK-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HYPOALLERGENIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HYPOALLERGENIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY HYPOALLERGENIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SOY-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SOY-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SOY-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADJUNCTIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PROBIOTIC THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PROBIOTIC THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PROBIOTIC THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ENTERIC-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ENTERIC-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ENTERIC-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY NON-ENTERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY NON-ENTERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY NON-ENTERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CHILDREN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 209. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 212. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 242. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 245. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 247. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 253. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 255. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 256. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 258. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY ANIMAL FEED, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY DIETARY SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FUNCTIONAL FOODS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY INFANT FORMULA, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS M-63 MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)

TABLE 271

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!